Skip to main content
ENTA
NASDAQ Life Sciences

Enanta Q3 Loss Narrows, RSV Drug Advances to Late-Stage Trials

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$13.81
Mkt Cap
$401.572M
52W Low
$6.45
52W High
$17.15
52W Position info
114% above low
Off High info
19% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ENTA has more than doubled off its 52-week low of $6.45.

Summary

Enanta reported a fiscal Q3 net loss of $19.5M ($0.67/share) on $14.4M in royalty revenue, with cash of $211.5M expected to fund operations into fiscal 2029. The loss narrowed from $0.85/share a year ago, but revenue declined from $18.3M due to lower AbbVie HCV sales. More importantly, the company disclosed significant pipeline progress: dosing has begun in the LOTUS Phase 2b pediatric RSV trial, and a registrational Phase 2b/3 trial (RESOLVE) in high-risk adults is set to start in Q4 2026, with initial data next year. In immunology, topline Phase 1 data for EDP-978 is due in Q4 2026, and an IND filing for STAT6 inhibitor EPS-3903 is planned this year. These updates follow the recent $75M ATM offering and the June patent loss on Paxlovid, adding clinical catalysts that could reshape the outlook. The RSV program's advancement into registrational trials is a key value driver, with no approved antiviral therapies currently available.

At the time of this announcement, ENTA was trading at $13.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $6.45 to $17.15. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ENTA - Latest Insights

ENTA
Nov 18, 2026, 7:00 AM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $8.99
Real-time Price: $7.84 info
Change: -$1.15 (-13%) info
Market Cap: $227.439M info
ENTA
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $7.84 info
Change: -$2.57 (-25%) info
Market Cap: $227.439M info
ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $7.84 info
Change: -$2.82 (-26%) info
Market Cap: $227.439M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $7.84 info
Change: -$3.31 (-30%) info
Market Cap: $227.439M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $7.84 info
Change: -$4.15 (-35%) info
Market Cap: $227.439M info